Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib dose escalation after resistance to 400 mg/day in advanced GIST
ChiCTR-TNC-09000585Phase 3Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival. Started Apr 2004; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR-TNC-09000585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-09000585.